However, in about 20% of prostate cancers, these treatments may trigger differentiation of adeno-CRPC towards aggressive anaplastic and neuroendocrine tumors that are associated with loss of canonical AR activity. This evidence concerns the gene AR and neuroendocrine neoplasm.